文献速递乳腺癌

IMpassion132双盲随机III期试验:化疗联合或不联合阿替利珠单抗治疗早期复发不可切除局部晚期或转移性三阴性乳腺癌

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2024-05-15

IMpassion132研究纳入末次化疗或早期三阴性乳腺癌手术后12个月内复发的不可切除局部晚期或转移性三阴性乳腺癌患者,按1:1随机接受安慰剂或阿替利珠单抗1200 mg每21天联合研究者选择的化疗。在354例PD-L1阳性快速复发患者中,总生存风险比为0.93(95%CI 0.73-1.20,P=0.59),中位总生存安慰剂组11.2个月 vs 阿替利珠单抗组12.1个月,未达统计学显著。结论认为在化疗基础上加用阿替利珠单抗未改善总生存。

要点

  • PD-L1阳性快速复发aTNBC患者中,阿替利珠单抗联合化疗对比安慰剂联合化疗的总生存HR为0.93(95%CI 0.73-1.20,P=0.59),未达统计学显著。
  • 中位无进展生存期在各治疗组和人群中均为4个月。
  • 客观缓解率安慰剂组为28%,阿替利珠单抗组为40%。

核心结论

  • 在12个月内复发的三阴性乳腺癌患者中,总生存极差,化疗基础上加用阿替利珠单抗未改善总生存。
  • 亟需在下一代临床试验中基于生物学定义aTNBC对免疫治疗的原发性耐药,以开发新疗法。

研究设计与样本

  • IMpassion132(NCT03371017)是一项双盲随机III期试验,纳入末次化疗剂量(需含蒽环类和紫杉类)或早期三阴性乳腺癌手术后12个月内复发的aTNBC患者。
  • PD-L1状态在随机化前采用SP142集中评估;初期入组不限PD-L1状态,自2019年8月起入组限制为PD-L1阳性(肿瘤免疫细胞≥1%)aTNBC。
  • 患者按1:1随机接受安慰剂或阿替利珠单抗1200 mg每21天联合研究者选择的化疗,直至疾病进展或不可接受的毒性。
  • 分层因素为化疗方案(卡铂联合吉西他滨或卡培他滨单药)、内脏(肺和/或肝)转移和(初期)PD-L1状态。
  • 主要终点为总生存,先在PD-L1阳性肿瘤患者中按层次检验,若阳性再在改良意向治疗(mITT)人群(2019年8月前随机化的所有患者)中检验;次要终点包括无进展生存期、客观缓解率和安全性。

主要发现

  • 354例快速复发PD-L1阳性aTNBC患者中,68%的无病间期<6个月,73%接受卡铂/吉西他滨。
  • 总生存风险比为0.93(95%CI 0.73-1.20,P=0.59;中位总生存安慰剂组11.2个月 vs 阿替利珠单抗组12.1个月)。
  • mITT和亚组结果一致。
  • 中位无进展生存期在各治疗组和人群中均为4个月。
  • 客观缓解率安慰剂组为28%,阿替利珠单抗组为40%;不良事件(主要为血液学毒性)两组相似,与近期化疗暴露后阿替利珠单抗联合卡铂/吉西他滨或卡培他滨的预期一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce. PATIENTS AND METHODS: IMpassion132 (NCT03371017) enrolled patients with aTNBC relapsing <12 months after last chemotherapy dose (anthracycline and taxane required) or surgery for early TNBC. PD-L1 status was centrally assessed using SP142 before randomisation. Initially patients were enrolled irrespective of PD-L1 status. From August 2019, enrolment was restricted to PD-L1-positive (tumour immune cell ≥1%) aTNBC. Patients were randomised 1:1 to placebo or atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy until disease progression or unacceptable toxicity. Stratification factors were chemotherapy regimen (carboplatin plus gemcitabine or capecitabine monotherapy), visceral (lung and/or liver) metastases and (initially) PD-L1 status. The primary endpoint was overall survival (OS), tested hierarchically in patients with PD-L1-positive tumours and then, if positive, in the modified intent-to-treat (mITT) population (all-comer patients randomised pre-August 2019). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and safety. RESULTS: Among 354 patients with rapidly relapsing PD-L1-positive aTNBC, 68% had a disease-free interval of <6 months and 73% received carboplatin/gemcitabine. The OS hazard ratio was 0.93 (95% confidence interval 0.73-1.20, P = 0.59; median 11.2 months with placebo versus 12.1 months with atezolizumab). mITT and subgroup results were consistent. Median PFS was 4 months across treatment arms and populations. ORRs were 28% with placebo versus 40% with atezolizumab. Adverse events (predominantly haematological) were similar between arms and as expected with atezolizumab plus carboplatin/gemcitabine or capecitabine following recent chemotherapy exposure. CONCLUSIONS: OS, which is dismal in patients with TNBC relapsing within <12 months, was not improved by adding atezolizumab to chemotherapy. A biology-based definition of intrinsic resistance to immunotherapy in aTNBC is urgently needed to develop novel therapies for these patients in next-generation clinical trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Dent R, André F, Gonçalves A, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024. PMID: 38755096. doi:10.1016/j.annonc.2024.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。